Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis ...Middle East

Oral PL8177 may provide a safe, effective, and tolerable treatment option for ulcerative colitis patients prior to immunosuppressive therapies and steroid treatments, which have significant safety and tolerability concerns Preclinical data demonstrated that oral PL8177 caused diseased...

Read More Details
Finally We wish PressBee provided you with enough information of ( Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis )

Also on site :

• Donald Trump and South Africa’s “White Genocide”
• Israeli bombing kills two civilians, injures others in Gaza
• Nightclubs affected as younger people shun nights out and stay at home instead